ENG抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-3: HepG2, Jurkat and MCF-7 cell lysates, Primary antibody: P08114(ENG Antibody) at dilution 1/650, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08114(ENG Antibody) at dilution 1/80. (Original magnification: ×200)    

  
  

ENG antibodies target endoglin (CD105), a transmembrane glycoprotein predominantly expressed on vascular endothelial cells. As a coreceptor in the TGF-β signaling pathway, endoglin regulates angiogenesis, vascular remodeling, and endothelial cell proliferation. Its overexpression is linked to pathological angiogenesis in cancers and vascular diseases.

First characterized in the 1990s, ENG antibodies emerged as critical tools for studying endothelial biology. They help distinguish activated endothelial cells (high endoglin) from quiescent ones in tumors or inflamed tissues. Clinically, ENG serves as a biomarker for hereditary hemorrhagic telangiectasia (HHT), where genetic mutations cause vascular malformations. Anti-ENG immunohistochemistry aids in diagnosing HHT-related vascular lesions and assessing tumor microvessel density as a prognostic indicator in cancers.

Therapeutically, ENG-targeting antibodies like carotuximab (TRC105) have been developed to inhibit angiogenesis in solid tumors by blocking TGF-β/endoglin pathways. Recent research also explores ENG antibody-conjugated nanoparticles for targeted drug delivery. Challenges remain in optimizing specificity and minimizing off-target effects, but ENG antibodies continue to bridge translational research and clinical applications in vascular disorders and oncology.